Evaluation of the structural development potential of receptors based on SARS-CoV-2 infection

Mila Chen; Jinghan Li

doi:10.54097/hset.v54i.9796

Authors

Mila Chen
Jinghan Li

DOI:

https://doi.org/10.54097/hset.v54i.9796

Keywords:

ACE2, SARS-CoV, S-Glycoprotein, Receptor Binding, subunit.

Abstract

Since 2019, the coronavirus has posed a huge threat to human health and the environment. Many scholars have since started studying the coronavirus and its branches, including SARS-CoV-2. SARS-CoV-2 is a positive stranded RNA virus composed of four main proteins and several auxiliary proteins that encapsulate genetic material. It mainly mediates virus invasion through the binding of S protein to host cell receptors, determining the tissue and host preference of the virus. ACE2 is a receptor required for SARS-CoV-2 to enter cells, which is consistent with the epidemiological risk of severe diseases observed in Chinese cardiovascular disease and hypertension patients. This article will explore the potential development of SARS-CoV-2 receptor ACE2 in terms of structure.

Downloads

Download data is not yet available.

References

Zhou P. Yang X.L.Wang X.G.Hu B.Zhang L.Zhang W.Si H.R.Zhu Y. Li B. Huang C.L.et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, 579: 270 - 273.

Tortorici M. A. Veesler D. Structural insights into coronavirus entry. Adv. Virus Res, 2019, 105: 93 - 116.

Belouzard S. Chu V. C. Whittaker G. R. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl. Acad. Sci. USA, 2009, 106: 5871 - 5876.

Madu I. G. Roth S. L. Belouzard S. Whittaker G. R. Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide. J. Virol, 2009, 83: 7411 - 7421.

D.S. Dimitrov, Virus entry: molecular mechanisms and biomedical applications, Nat. Rev. Microbiol., 2004 (in press).

Chen Lei Li Yanping Yu Min; Analysis of Differences between SARS-CoV-2 and SARS Coronavirus (SARS-CoV) from Multiple Perspectives. College of Pharmacy, Jiangsu Vocational College of Medicine, Yancheng, 224005.

Gavin Y. Oudit, Kaiming Wang, Anissa Viveiros, Max. Kellner Josef. M. Penninger. Angiotensin Converting Enzyme 2 - at the Heart of the COVID-19 pandemic.

Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin I Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized with COVID - 19. 2020, 126 (12): 1671 - 1681.

Jing W, Procko E. ACE2-based decoy receptors for SARS coronavirus 2. Proteins, 2021, 89 (9): 1065 - 1078.

Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, Romero JP, Wirnsberger G, Zhang H, Slutsky AS, Conder R, Montserrat N, Mirazimi A, Penninger JM. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell, 2020, 181 (4): 905 - 913.e7.

Jing W, Procko E. ACE2-based decoy receptors for SARS coronavirus 2. Proteins, 2021, 89 (9): 1065 - 1078.

E. Jonasch, J. Gao, W. K. Rathmell, Renal cell carcinoma. BMJ 349, g4797.

Khanna P, Soh HJ, Chen CH, Saxena R, Amin S, Naughton M, Joslin PN, Moore A, Bakouny Z, O'Callaghan C, Catalano P, Signoretti S, McKay R, Choueiri TK, Bhasin M, Walther T, Bhatt RS. ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. Sci Transl Med, 2021, 13 (577): eabc0170.

Rice GI, Jones AL, Grant PJ, et al. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension, 2006, 48 (5): 914 - 920.

Sahara M, Ikutomi M, Morita T, et al. Deletion of angiotensin-converting enzyme 2 promotes the development of atherosclerosis and arterial neointima formation. Cardiovasc Res, 2014, 101 (2): 236 - 246.

Sluimer JC, Gasc JM, Hamming I, et al. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions.

Zulli A, Burrell LM, Buxton BF, et al. ACE2 and AT4R are present in diseased human blood vessels. Eur J Histochem, 2008, 52 (1): 39 - 44.